Table 2.

Fold change of genes in PC-3 cells exposed to combination treatment or mono-treatment with docetaxel or estramustine

Docetaxel + Estramustine
Cell proliferation and apoptosis
    NM_006739 cell division cycle 46NC−1.5−2.6−1.2−1.5−2.1−1.1−1.3−2.5
    U77949 Cdc6-related protein (HsCDC6)0.3−1.9−2.0NC−1.7−2.01.4−2.6−1.9
    NM_005983 S phase kinase-associated protein 2 (SKP2)−0.2−2.1−3.7−1.2−3.0−3.2NC−1.7−2.1
    NM_002634 prohibitin (PHB)NC−1.4−3.0NC−1.1−2.8NC−2.6−3.0
    NM_003132 spermidine synthase (SRM)NC−1.5−2.5NC−1.4−2.0NC−1.4−2.3
    NM_014303 pescadilloNC−1.5−2.3NCNC−2.81.4−2.3−2.3
    NM_003242 transforming growth factor, β receptor II (TGFBR2)−0.8−1.6−2.0−2.8−4.3−1.7−1.9−1.3−2.1
    L49506 cyclin G2 mRNA−−−
    BC001971Similar to cyclin-dependent kinase inhibitor 1B (p27, Kip1)
    NM_001731 B cell translocation gene 1, antiproliferative (BTG1)NC1.−
    NM_006472 up-regulated by 1,25-dihydroxyvitamin D3 (VDUP1)1.32.1−2.0NC2.
    NM_014330 growth arrest and DNA-damage-inducible 34 (GADD34)
    NM_015675 growth arrest and DNA-damage-inducible, β (GADD45B)
    AF087853 growth arrest and DNA damage inducible protein β (GADD45B)NC2.
    AF078077 growth arrest and DNA-damage-inducible protein GADD45β1.
    NM_014456 programmed cell death 4 (PDCD4)NC1.
Oncogenesis and cancer aggressiveness
    NM_001511 GRO1 oncogene2.0−1.5−3.01.9−1.3−2.61.9−6.1−11.3
    NM_002090 GRO3 oncogene (GRO3)2.8−3.0−4.02.5−1.6−2.52.5−5.7−8.0
    NM_007045 FGFR1 oncogene partner (FOP)−0.1−1.6−2.6−1.1−1.1−2.5NC−2.0−2.6
    AF061832.1 M4 protein deletion mutant mRNANC−1.7−2.1NC−1.2−3.7NC−3.2−3.5
    NM_004501 heterogeneous nuclear ribonucleoprotein U (HNRPU)NC−1.5−2.5NC−1.5−2.6NC−1.9−2.5
    NM_005789 proteasome activator subunit 3 (PA28 γ)NC−1.4−2.6NC−1.2−2.0NC−1.7−2.8
    NM_006392 nucleolar protein (NOP56)NC−2.0−3.5−1.1−1.3−4.3NC−2.6−3.7
    NM_006851 glioma pathogenesis-related protein (RTVP1)2.0−2.0−1.72.0−1.2−2.02.3−2.1−1.7
    M80261 apurinic endonuclease (APE)1.1−1.4−3.0−1.1−1.3−3.0NC−1.6−2.1
    NM_006850 suppressor of tumorigenicity 16 (ST16)
Transcription and translation
    NM_012068 activating transcription factor 5 (ATF5)NC−2.1−3.5NC−2.1−4.0NC−2.3−2.5
    NM_007111 transcription factor Dp-1 (TFDP1)NC−1.6−3.2NC−1.7−2.5NC−1.7−2.3
    NM_012251 transcription factor A, mitochondria (TFAM)1.3−1.5−2.5NC−1.7−2.1NC−2.3−2.8
    AF220509 transcription associated factor TAFII31LNC−2.3−3.2NC−4.6−1.7NC−1.7−2.3
    NM_001412 eukaryotic translation initiation factor 1A (EIF1A)−0.1−1.3−2.3NC−1.1−2.6NC−1.4−2.3
    NM_002546 osteoprotegerin1.5−1.3−3.01.2−1.3−3.71.7−2.1−1.7
    NM_001674 activating transcription factor 3 (ATF3)1.41.914.
Invasion, metastasis, differentiation, and others
    AF092095 metastasis-suppressor gene CC3 (TC3)
    AF021834 tissue factor pathway inhibitor β (TFPIβ)−
    AF021834 tissue factor pathway inhibitor β (TFPIβ)NC3.712.
    NM_001908 cathepsin B (CTSB)
    NM_000930 plasminogen activator, tissue (PLAT)
    NM_002658 plasminogen activator, urokinase (PLAU)NC2.
    M92934 connective tissue growth factor2.
    AF003934 prostate differentiation factor mRNA−1.54.326.0−
    NM_005345 heat shock 70 kDa protein 1A (HSPA1A)
    NM_005346 heat shock 70 kDa protein 1B (HSPA1B)
    NM_000435 Notch (Drosophila) homologue 3 (NOTCH3)NC2.−
    U73191 inward rectifier potassium channel (Kir1.3)NC6.
Resistance to chemotherapeutic agents
    NM_001894 casein kinase 1 (CSNK1E)NC1.73.2NC1.73.0NC1.62.1
    AU154504 cytochrome P450, subfamily I (dioxin-inducible)NC1.12.1NCNC2.5NC2.02.1
    AU144855 cytochrome P450, subfamily I (dioxin-inducible)NC1.52.1NC1.32.5NC2.32.6
    NM_005980 S100 calcium-binding protein P (S100P)−1.24.924.−
  • NOTE: The genes in this list have a >2-fold change in expression in at least one time point in both mono- and combination treatment (P < 0.05); NC, no change; negative values, decrease; positive values, increase.